Suppliers / Avara Pharmaceutical Technologies
Avara Pharmaceutical Technologies
United States Updated 9 July 2026
Avara Pharmaceutical Technologies is a finished-dose manufacturer based in United States. It appears in 3 regulatory filings across 2 regulators, without an active US DMF or CEP on file. Its filings concentrate with NPRA (MY) and UZPHARM (UZ). Its GMP standing is certified by MFDS (Korea), ANVISA (Brazil) and EAEU_EEC. Its most recent recorded inspection, by US FDA, closed on 31 October 2022 as NAI.
2
registered plants
1 with an FDA FEI number
3
filings
across 2 regulators
These figures were checked against the regulators' own files on 25 July 2026
Inspections
4 of 4 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.
Inspection history
- 31 October 2022 NAI US FDA
- 26 September 2018 VAI US FDA
- 30 March 2012 NAI US FDA
- 27 September 2010 NAI US FDA
NAI means no action indicated, VAI means voluntary action indicated, and OAI means
official action indicated.
Registered plants
| Site | FDA FEI |
| NORMAN, United States | Not on file |
| Norman, United States | 3004998655 |
Filings and GMP by regulator
| Regulator | Filings | GMP certificates |
| NPRA (MY) | 2 | None |
| UZPHARM (UZ) | 1 | None |
| MFDS (Korea) | None | 2 |
| ANVISA (Brazil) | None | 1 |
| EAEU_EEC | None | 1 |
Comparing suppliers?
Choose your molecules and target markets. Avara Pharmaceutical Technologies comes back tiered against every other
supplier able to file there.
Start for free No sales call.
Open risk flags
- The most recent inspection outcome was NAI, on 31 October 2022.
Sources on this page
- FDA
- Drug master files, establishment registration, inspection classifications
- EDQM
- Certificates of suitability
- EudraGMDP and national regulators
- GMP certificates